All News

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.

A phase 1 study will evaluate TERN-701’s safety, efficacy, and pharmacokinetics in a population diagnosed with chronic myeloid leukemia.

Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.

Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.

Data from a phase 2 trial suggests that earlier use of abiraterone acetate/prednisone plus cabazitaxel may elicit clinical benefit in patients with metastatic castration-resistant prostate cancer.

Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

Objective response rate appears to be higher with datopotamab deruxtecan compared with docetaxel among patients with advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 study.

ERBB2, FAT3, and FRS2 alterations appear to correlate with improved progression-free survival with ribociclib compared with placebo in patients with advanced breast cancer.

Julie M. Vose, MD, MBA, reflects on the generic drug shortages and the reasoning behind the continued pattern affecting different cancer types.

Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.

Data from the phase 3 KEYNOTE-775 trial support lenvatinib plus pembrolizumab as a standard therapy option for patients with previously treated advanced endometrial cancer.

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.

Median radiographic progression-free survival appears to be higher in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 than those receiving androgen receptor pathway inhibitors.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for those with hormone receptor–positive breast cancer.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.

Data from the phase 3 RUBY trial may support the use of dostarlimab plus chemotherapy as a new standard of care in patients with newly diagnosed primary advanced or recurrent endometrial carcinoma.

Trastuzumab deruxtecan produces enduring responses among patients with HER2-mutated solid tumors in the phase 2 DESTINY-PanTumor01 trial.

Data from the phase 3 EV-302 trial support enfortumab vedotin plus pembrolizumab as a potential standard of care in locally advanced or metastatic urothelial carcinoma.

Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.

Sotorasib plus panitumumab demonstrate consistent efficacy across key patient subgroups with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations in the phase 3 CodeBreaK 300 trial.

Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.

Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.

Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.